Janus Henderson

Stories

The race to replace reading glasses

Co-led Tenpoint's $85M Series B financing

For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia. On October 16, 2026, the agency approved a fourth drop, RYZUMVI (phentolamine ophthalmic solution 0.75%) from Viatris, widening the market.

Updated Oct 17

Janus Henderson cleared to go private in Trian-led buyout

Money Moves

As of June 2026: Target of the take-private; to be delisted from the NYSE

Trian Fund Management started buying Janus Henderson stock in 2020. Now it is buying the whole company. On June 18, 2026, Janus Henderson said it had the regulatory clearances and client consents to finish a deal that takes the firm private and off the New York Stock Exchange.

Updated Jun 18